Trial Profile
A Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination With Gemcitabine-based Chemotherapy as First Line Treatment for Chinese Patients With Unresectable Biliary Tract Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer
- Focus Adverse reactions; Registrational
- Acronyms TopDouble
- Sponsors AstraZeneca
- 05 Mar 2024 Status changed from recruiting to active, no longer recruiting.
- 03 Aug 2023 Status changed from not yet recruiting to recruiting.
- 03 Jul 2023 New trial record